Human medicines European public assessment report (EPAR): Loargys, pegzilarginase, Date of authorisation: 15/12/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Loargys, pegzilarginase, Date of authorisation: 15/12/2023, Revision: 5, Status: Authorised

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations - 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 November 2025, 09:

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations - 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 November 2025, 09:00 (CET) to 18 November 2025, 17:30 (CET)

Human medicines European public assessment report (EPAR): Inbrija, levodopa, Date of authorisation: 19/09/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Inbrija, levodopa, Date of authorisation: 19/09/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Gohibic, vilobelimab, Date of authorisation: 13/01/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Gohibic, vilobelimab, Date of authorisation: 13/01/2025, Revision: 2, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness